Results 11 to 20 of about 2,404 (154)
Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
VaccinesRespiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Pan-Pan Wu, Fang-Rui Ding
doaj +4 more sources
Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain [PDF]
VaccinesBackground/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease.
Sara Jimeno Ruiz +7 more
doaj +4 more sources
Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy [PDF]
VaccinesBackground: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the ...
Susanna Esposito +10 more
doaj +3 more sources
VaccinesRespiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Guillermo Ezpeleta +15 more
doaj +4 more sources
Nature Communications, 2023 Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani +20 more
doaj +2 more sources
Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System [PDF]
Journal of Pediatrics: Clinical PracticeObjective: To describe the uptake of respiratory syncytial virus (RSV) prevention products during the first 2 seasons after availability in the US in a large health system. Study design: Using multisource immunization data from a single health system, we
Jessica E. Kerr, MPH +3 more
doaj +2 more sources
Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]
BMJ Paediatrics OpenObjective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti +13 more
doaj +2 more sources
PathogensBackground: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV
Vaishali S. Mankad +8 more
doaj +3 more sources
Clinical and Translational ScienceRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao +12 more
doaj +2 more sources
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection [PDF]
Frontiers in Immunology, 2023 IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady +9 more
doaj +2 more sources